CXCR1与恶性肿瘤的相关性

doi:10.3760/cma.j.cn371439-20200419-00110

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (12): 732-736.doi: 10.3760/cma.j.cn371439-20200419-00110

CXCR1与恶性肿瘤的相关性

刘彦权, 沈建箴()

福建省血液病研究所国家及福建省血液病学重点实验室福建医科大学附属协和医院血液内科,福州 350001

收稿日期:2020-04-19 修回日期:2020-05-18 出版日期:2020-12-08 发布日期:2021-01-28
通讯作者: 沈建箴 E-mail:doctorsjz@163.com
基金资助:
福建省科技创新联合资金项目(2018Y9010);福建省卫生计生科研人才培养项目(2016-ZQN-29);福建省卫生计生科研人才培养项目(2018-ZQN-40)

Correlation between CXCR1 and malignant tumors

Liu Yanquan, Shen Jianzhen()

Fujian Institute of Hematology, National and Fujian Provincial Key Laboratory of Hematology, Department of Hematopathology, Fujian Medical University Union Hospital, Fuzhou 350001, China

Received:2020-04-19 Revised:2020-05-18 Online:2020-12-08 Published:2021-01-28
Contact: Shen Jianzhen E-mail:doctorsjz@163.com
Supported by:
Joints Funds for the Innovation of Science and Technology of Fujian Province(2018Y9010);Health and Family Planning Research Personnel Training Program of Fujian Province(2016-ZQN-29);Health and Family Planning Research Personnel Training Program of Fujian Province(2018-ZQN-40)

摘要/Abstract

摘要：

作为G蛋白偶联受体超家族的重要成员,CXC趋化因子受体1(CXCR1)是CXC趋化因子白细胞介素-8最重要且颇具亲和力的受体之一。CXCR1常表达于中性粒细胞、单核细胞、T细胞等细胞表面,并且可与CXC趋化因子配体(CXCL)6、CXCL7、CXCL8相结合。研究发现CXCR1在促进恶性肿瘤转移、化疗耐药以及维持肿瘤干细胞特性中发挥至关重要的作用,下调CXCR1表达能显著抑制恶性肿瘤的生物学特性。目前学术界将CXCR1视为恶性肿瘤的原癌基因,CXCR1有望成为恶性肿瘤诊断和治疗的潜在靶点。

关键词: 受体, 趋化因子, 受体, 白细胞介素8A, 趋化因子, CXC, 肿瘤

Abstract:

As an important member of the G protein coupled receptor superfamily, CXC chemokine receptor 1 (CXCR1) is also one of the most important and affinity receptors for CXC chemokine interleukin 8. CXCR1 is often expressed on the surface of cells such as neutrophils, monocytes and T cells, which can bind to CXC chemokine ligand (CXCL)6, CXCL7 and CXCL8. Studies have found that CXCR1 plays a vital role in promoting the metastasis, chemotherapy resistance and maintaining the characteristics of tumor stem cells. Down-regulating the expression of CXCR1 can significantly inhibit the biological characteristics of malignant tumors. At present, the academic field regards CXCR1 as the proto-oncogene of malignant tumors. CXCR1 is expected to become a potential target for the diagnosis and treatment of malignant tumors.

Key words: Receptors, chemokine, Receptors, interleukin-8A, Chemokines, CXC, Neoplasms

刘彦权, 沈建箴. CXCR1与恶性肿瘤的相关性[J]. 国际肿瘤学杂志, 2020, 47(12): 732-736.

Liu Yanquan, Shen Jianzhen. Correlation between CXCR1 and malignant tumors[J]. Journal of International Oncology, 2020, 47(12): 732-736.

参考文献 34

[1]	Fu Q, Yang Y, Li C, et al. The chemokinome superfamily:Ⅱ. The 64 CC chemokines in channel catfish and their involvement in disease and hypoxia responses[J]. Dev Comp Immunol, 2017,73:97-108. DOI: 10.1016/j.dci.2017.03.012. pmid: 28322933
[2]	Sakai H, Yabe S, Sato K, et al. ELR⁺ chemokine-mediated neutrophil recruitment is involved in 2,4,6-trinitrochlorobenzene-induced contact hypersensitivity[J]. Clin Exp Pharmacol Physiol, 2018,45(1):27-33. DOI: 10.1111/1440-1681.12839.
[3]	Wang Y, Cecylia SL, Wang T, et al. A computational study of the chemokine receptor CXCR1 bound with interleukin-8[J]. Chin Phys B, 2018,27(3): 038702-1-038702-10. DOI: 10.1088/1674-1056/27/3/038702.
[4]	Bishayi B, Adhikary R, Sultana S, et al. Altered expression of CXCR1 (IL-8R) in macrophages utilizing cell surface TNFR1 and IL-1 receptor during Staphylococcus aureus infection[J]. Microb Pathog, 2017,113:460-471. DOI: 10.1016/j.micpath.2017.11.028.
[5]	Ng YY, Tay JCK, Wang S. CXCR1 Expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts[J]. Mol Ther Oncolytics, 2019,16:75-85. DOI: 10.1016/j.omto.2019.12.006. doi: 10.1016/j.omto.2019.12.006 pmid: 31970285
[6]	毕惠娟, 陈建民, 陈静静, 等. 原发性肝癌患者CXCR1、CXCR2及CXCL8的表达及其临床意义[J]. 中华微生物学和免疫学杂志, 2017,37(7):545-551. DOI: 10.3760/cma.j.issn.0254-5101.2017.07.012.
[7]	Yu J, Ren X, Chen Y, et al. Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients[J]. PLoS One, 2013,8(2):e56069. DOI: 10.1371/journal.pone.0056069. doi: 10.1371/journal.pone.0056069 pmid: 23418512
[8]	An Z, Li J, Yu J, et al. Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages[J]. Cell Cycle, 2019,18(21):2928-2938. DOI: 10.1080/15384101.2019.1662678.
[9]	Bi H, Zhang Y, Wang S, et al. Interleukin-8 promotes cell migration via CXCR1 and CXCR2 in liver cancer[J]. Oncol Lett, 2019,18(4):4176-4184. DOI: 10.3892/ol.2019.10735.
[10]	Wang Z, Liu H, Shen Z, et al. The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients[J]. BMC Cancer, 2015,15:766. DOI: 10.1186/s12885-015-1793-9. pmid: 26497045
[11]	Jia X, Lu M, Rui C, et al. Consensus-expressed CXCL8 and MMP9 identified by meta-analyzed perineural invasion gene signature in gastric cancer microarray data[J]. Front Genet, 2019,10:851. DOI: 10.3389/fgene.2019.00851. doi: 10.3389/fgene.2019.00851 pmid: 31681401
[12]	Chen X, Chen R, Jin R, et al. The role of CXCL chemokine family in the development and progression of gastric cancer[J]. Int J Clin Exp Pathol, 2020,13(3):484-492.
[13]	余亮, 周国强, 余生元, 等. 白细胞介素8及白细胞介素受体1信号轴在胃癌组织中的临床意义[J]. 中华老年医学杂志, 2018,37(4):427-430. DOI: 10.3760/cma.j.issn.0254-9026.2018.04.017.
[14]	Cao Y, Liu H, Zhang H, et al. CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM Ⅱ and Ⅲ resectable gastric cancer patients[J]. Oncotarget, 2017,8(12):20328-20339. DOI: 10.18632/oncotarget.12815. pmid: 27780937
[15]	姚小健, 黄红霞, 陈勇, 等. CXCR1调控STAT3信号通路对结肠癌细胞增殖凋亡的影响[J]. 医学研究杂志, 2017,46(8):126-131. DOI: 10.11969/j.issn.1673-548X.2017.08.031.
[16]	Fisher RC, Bellamkonda K, Alex Molina L, et al. Disrupting inflammation-associated CXCL8-CXCR1 signaling inhibits tumori-genicity initiated by sporadic- and colitis-colon cancer stem cells[J]. Neoplasia, 2019,21(3):269-281. DOI: 10.1016/j.neo.2018.12.007. pmid: 30738331
[17]	Zhu Y, Liu Z, Wang Y, et al. High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients[J]. Oncoimmunology, 2017,6(11):e1359450. DOI: 10.1080/2162402X.2017.1359450. doi: 10.1080/2162402X.2017.1359450
[18]	Corrò C, Healy ME, Engler S, et al. IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer[J]. J Pathol, 2019,248(3):377-389. DOI: 10.1002/path.5267. doi: 10.1002/path.5267 pmid: 30883740
[19]	Wu S, Saxena S, Varney ML, et al. CXCR1/2 chemokine network regulates melanoma resistance to chemotherapies mediated by NF-κB[J]. Curr Mol Med, 2017,17(6):436-449. DOI: 10.2174/1566524018666171219100158. doi: 10.2174/1566524018666171219100158 pmid: 29256349
[20]	Kemp DM, Pidich A, Larijani M, et al. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment[J]. Oncotarget, 2017,8(9):14428-14442. DOI: 10.18632/oncotarget.14803. doi: 10.18632/oncotarget.14803 pmid: 28129639
[21]	Uen WC, Hsieh CH, Tseng TT, et al. Anchorage independency promoted tumor malignancy of melanoma cells under reattachment through elevated interleukin-8 and CXC chemokine receptor 1 expression[J]. Melanoma Res, 2015,25(1):35-46. DOI: 10.1097/CMR.0000000000000134.
[22]	BeLow M, Osipo C. Notch signaling in breast cancer: a role in drug resistance[J]. Cells, 2020,9(10):2204. DOI: 10.3390/cells9102204.
[23]	Wang X, Semba T, Phi LTH, et al. Targeting signaling pathways in inflammatory breast cancer[J]. Cancers (Basel), 2020,12(9):2479. DOI: 10.3390/cancers12092479.
[24]	Wang RX, Ji P, Gong Y, et al. Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study[J]. Breast Cancer Res Treat, 2020,181(3):561-570. DOI: 10.1007/s10549-020-05660-z.
[25]	Xue MQ, Liu J, Sang JF, et al. Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer[J]. Oncotarget, 2017,8(30):48930-48937. DOI: 10.18632/oncotarget.16893. doi: 10.18632/oncotarget.16893 pmid: 28454081
[26]	Khurram SA, Bingle L, McCabe BM, et al. The chemokine receptors CXCR1 and CXCR2 regulate oral cancer cell behaviour[J]. J Oral Pathol Med, 2014,43(9):667-674. DOI: 10.1111/jop.12191. doi: 10.1111/jop.12191 pmid: 24965032
[27]	Spaks A. Role of CXC group chemokines in lung cancer development and progression[J]. J Thorac Dis, 2017,9(Suppl 3):S164-S171. DOI: 10.21037/jtd.2017.03.61. doi: 10.21037/jtd.2017.03.61 pmid: 28446981
[28]	Han XG, Yang SB, Mo HM, et al. Targeting of CXCR1 on osteosarcoma circulating tumor cells and precise treatment via cisplatin nanodelivery[J]. Adv Fun Mater, 2019,29(34):1902246. DOI: 10.1002/adfm.201902246.
[29]	Wang J, Hu W, Wang K, et al. Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil[J]. Int J Oncol, 2016,48(4):1341-1352. DOI: 10.3892/ijo.2016.3371. doi: 10.3892/ijo.2016.3371 pmid: 26847910
[30]	Shang FM, Li J. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway[J]. Med Clin (Barc), 2019,152(11):425-430. DOI: 10.1016/j.medcle.2018.08.016. doi: 10.1016/j.medcli.2018.08.006
[31]	Liu X, Peng J, Sun W, et al. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice[J]. Tohoku J Exp Med, 2012,228(2):147-156. DOI: 10.1620/tjem.228.147. doi: 10.1620/tjem.228.147
[32]	Goldstein LJ, Perez RP, Yardley D, et al. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer[J]. Breast Cancer Res, 2020,22(1):4. DOI: 10.1186/s13058-019-1243-8. doi: 10.1186/s13058-019-1243-8 pmid: 31924241
[33]	Li X, Zhang Y, Walana W, et al. GDC-0941 and CXCL8 (3-72) K11R/G31P combination therapy confers enhanced efficacy against breast cancer[J]. Future Oncol, 2020,16(14):911-921. DOI: 10.2217/fon-2020-0035. doi: 10.2217/fon-2020-0035 pmid: 32285685
[34]	Susek KH, Karvouni M, Alici E, et al. The role of CXC chemokine receptors 1-4 on immune cells in the tumor microenvironment[J]. Front Immunol, 2018,9:2159. DOI: 10.3389/fimmu.2018.02159. doi: 10.3389/fimmu.2018.02159 pmid: 30319622

CXCR1与恶性肿瘤的相关性

Correlation between CXCR1 and malignant tumors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.